Drug Trial Radar · NCT07883213
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Aug 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Oct 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of subjects with prurigo nodularis. The total duration of the study (including screening period, treatment period and follow-up period) planned for each subject is approximately 24 weeks.
Conditions
- Prurigo Nodularis (PN)
Interventions
AK139Biological
Biological: AK139 low dose
PlaceboOther
Other: Placebo
AK139Biological
Biological: AK139 high dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with ≥4-point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at week 16Time frame: Up to week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.